Bristol Myers Squibb (BMS) stands at the forefront of pharmaceutical innovation, leveraging gene editing technologies to revolutionize treatments for cancer, autoimmune diseases, and other serious conditions. Through strategic partnerships and in-house advancements, BMS is shaping the future of precision medicine.
Image Credit: Radiology Business
Gene editing involves precise alterations to the DNA within living cells, enabling the correction of genetic defects, modification of disease-related genes, or enhancement of cellular functions. Techniques like CRISPR, base editing, and prime editing allow for targeted interventions, offering potential cures for previously untreatable diseases.
Oncology & Hematology Focus: Developing gene-edited therapies primarily for cancer and blood-related diseases.
Next-Generation Cell Therapies: Pioneering engineered T cell receptors (eTCRs) and CAR T cell therapies for enhanced effectiveness.
Research & Development: Exploring innovative gene editing techniques (CRISPR, base editing, prime editing) for targeted therapies.
Clinical Trials: Conducting studies to evaluate safety, efficacy, and long-term outcomes of gene-edited therapies.
The global gene editing therapeutics market is experiencing rapid growth, projected to generate hundreds of millions in revenue between 2025 and 2034. This expansion is driven by rising investments, technological innovation, and growing demand across multiple sectors.
BMS’s gene editing initiatives encompass:
Research and Development: Exploring innovative gene editing techniques to create targeted therapies.
Clinical Trials: Conducting studies to evaluate the safety and efficacy of gene-edited therapies.
Manufacturing: Developing scalable processes for the production of gene-edited cell therapies.
Regulatory Affairs: Navigating the approval processes with agencies like the FDA to bring therapies to market.
Patient Access: Ensuring equitable access to advanced therapies through collaborations and infrastructure development.
Manufacturing Complexity – Gene-edited therapies require complex production. BMS partnered with Cellares ($380M) to improve CAR-T cell therapy manufacturing.
Regulatory Hurdles – Approvals are complicated. BMS streamlined patient monitoring and removed REMS programs for some therapies to ease access.
Access & Affordability – High costs limit availability. BMS is expanding treatment centers and collaborating with healthcare systems to improve patient access.
Therapy Safety & Efficacy – Ensuring gene-edited cells are safe and effective is critical. BMS invests in rigorous preclinical and clinical testing.
FDA Approvals: In 2025, the FDA approved label updates for BMS’s CAR T cell therapies, Breyanzi and Abecma, expanding their use in treating multiple myeloma.
Strategic Acquisitions: BMS acquired 2seventy bio for approximately $286 million, enhancing its CAR-T cell therapy portfolio and reducing future profit-sharing expenses.
Collaborations: The partnership with Prime Medicine focuses on developing gene-editing technologies to improve the potency of cell therapies
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
